A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6950 participants.

Also called NCT07761117

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,950 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07761117
  • EU CT 2026-526304-79-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Arab Emirates, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07761117. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2029-09-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Acronym
Elevate-HF
Condition
Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07761117
Content hash
78cd5621e82f2ff33aa2c9a0eb9cb8d915467094a7492539be48f39b48929f68